BIND Therapeutics
Is a clinical-stage nanomedicine platform company developing Accurins, a class of highly selective, targeted therapeutics.
Launch date
Employees
Cambridge Massachusetts (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
$2.5m | Series A | ||
| N/A | $16.0m | Series B | |
| N/A | $12.4m | Series C | |
| N/A | $4.8m | Debt | |
$25.5m | Series D | ||
| N/A | $8.7m | Early VC | |
| N/A | N/A | IPO | |
* | N/A | $22.0m | Post IPO Equity |
$40.0m | Acquisition | ||
| Total Funding | $65.1m | ||